Endocrine side effects induced by immune checkpoint inhibitors.

Toxicities of Immunotherapy for the Practitioner. J Clin Oncol (2015) 1.50

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer (2014) 1.32

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. Front Immunol (2014) 1.18

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol (2016) 1.12

Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res (2014) 1.05

Detection of pituitary antibodies by immunofluorescence: approach and results in patients with pituitary diseases. J Clin Endocrinol Metab (2014) 0.91

Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. Transl Res (2015) 0.87

Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. J Immunother Cancer (2016) 0.84

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. J Clin Endocrinol Metab (2016) 0.83

Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol (2017) 0.82

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front Pharmacol (2017) 0.81

Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res Int (2015) 0.80

Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. Int J Cancer (2014) 0.80

Immune checkpoint inhibitor therapy associated hypophysitis. Clin Med Insights Endocrinol Diabetes (2015) 0.79

Early phase clinical trials to identify optimal dosing and safety. Mol Oncol (2014) 0.78

Ipilimumab-induced autoimmune hypophysitis: a differential for sellar mass lesions. Endocrinol Diabetes Metab Case Rep (2014) 0.76

Endocrinopathies in survivors of childhood neoplasia. Front Pediatr (2014) 0.76

Checkpoint inhibition and melanoma: Considerations in treating the older adult. J Geriatr Oncol (2017) 0.76

Overcoming tumor immune evasion with an unique arbovirus. J Transl Med (2015) 0.75

Anticytotoxic T-lymphocyte antigen-4 induced autoimmune hypophysitis: a case report and literature review. Case Rep Endocrinol (2015) 0.75

Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma. Mol Clin Oncol (2016) 0.75

Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma. Case Rep Endocrinol (2016) 0.75

Exacerbation of Autoimmune Thyroiditis by CTLA-4 Blockade: A Role for IFNγ-Induced Indoleamine 2, 3-Dioxygenase. Thyroid (2016) 0.75

Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med (2016) 0.75

Acute Hyperglycemia Associated with Anti-Cancer Medication. Endocrinol Metab (Seoul) (2017) 0.75

Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine (2017) 0.75

Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer. Intern Med (2017) 0.75

Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists. Cancer Med (2017) 0.75

Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. J Clin Endocrinol Metab (2017) 0.75

Is Graves' disease a primary immunodeficiency? New immunological perspectives on an endocrine disease. BMC Med (2017) 0.75

Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity. F1000Res (2017) 0.75

Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci U S A (2004) 1.72

Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage (2004) 1.67

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med (2014) 1.59

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol (2009) 1.55

Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases. N Z Med J (2003) 1.47

Images in clinical medicine. Pemberton's sign. N Engl J Med (2004) 1.47

Growth Hormone Therapy Accelerates Axonal Regeneration, Promotes Motor Reinnervation, and Reduces Muscle Atrophy following Peripheral Nerve Injury. Plast Reconstr Surg (2016) 1.43

Perioperative glucocorticoid prescribing habits in patients with inflammatory bowel disease: a call for standardization. JAMA Surg (2014) 1.37

Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res (2007) 1.36

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat (2006) 1.29

Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. Eur J Hum Genet (2004) 1.29

Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab (2010) 1.24

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother (2014) 1.23

Familial isolated growth hormone deficiency is associated with increased systolic blood pressure, central obesity, and dyslipidemia. J Clin Endocrinol Metab (2002) 1.18

Lack of evidence of premature atherosclerosis in untreated severe isolated growth hormone (GH) deficiency due to a GH-releasing hormone receptor mutation. J Clin Endocrinol Metab (2006) 1.15

Congenital growth hormone (GH) deficiency and atherosclerosis: effects of GH replacement in GH-naive adults. J Clin Endocrinol Metab (2007) 1.14

Metabolic regulation of ghrelin O-acyl transferase (GOAT) expression in the mouse hypothalamus, pituitary, and stomach. Mol Cell Endocrinol (2009) 1.14

Physical exercise and quality of life in breast cancer survivors. Int J Med Sci (2008) 1.14

A mouse with targeted ablation of the growth hormone-releasing hormone gene: a new model of isolated growth hormone deficiency. Endocrinology (2004) 1.13

Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab (2009) 1.13

Glucocorticoid-induced loss of DNA methylation in non-neuronal cells and potential involvement of DNMT1 in epigenetic regulation of Fkbp5. Biochem Biophys Res Commun (2012) 1.12

Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer. Endocr Relat Cancer (2012) 1.12

Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer (2003) 1.10

Longevity in untreated congenital growth hormone deficiency due to a homozygous mutation in the GHRH receptor gene. J Clin Endocrinol Metab (2009) 1.09

On the shoulders of giants: Harvey Cushing's experience with acromegaly and gigantism at the Johns Hopkins Hospital, 1896-1912. Pituitary (2011) 1.09

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol (2014) 1.09

Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys (2002) 1.08

Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res (2006) 1.06

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest (2014) 1.06

The use of bevacizumab in non-small cell lung cancer: an update. Anticancer Res (2014) 1.06

Cushing syndrome: maybe not so uncommon of an endocrine disease. J Am Board Fam Med (2012) 1.04

Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother Pharmacol (2013) 1.03

Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist (2012) 0.99

Complete regression of a non-small cell lung cancer choroidal metastasis with intravitreal bevacizumab. J Thorac Oncol (2012) 0.98

Growth hormone-releasing hormone disruption extends lifespan and regulates response to caloric restriction in mice. Elife (2013) 0.97

Insulin sensitivity and β-cell function in adults with lifetime, untreated isolated growth hormone deficiency. J Clin Endocrinol Metab (2011) 0.96

Magnetic resonance imaging study of pituitary morphology in subjects homozygous and heterozygous for a null mutation of the GHRH receptor gene. Eur J Endocrinol (2003) 0.96

Circulating tumor cells in colorectal cancer patients. Cancer Treat Rev (2013) 0.96

Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol (2016) 0.96

Invasive adenoma and pituitary carcinoma: a SEER database analysis. Neurosurg Rev (2014) 0.94

Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. Clin Cancer Res (2006) 0.93

Dermoscopic patterns of cutaneous melanoma metastases. Melanoma Res (2004) 0.93

The Supportive Care Task Force at the University of L'Aquila: 2-years experience. Support Care Cancer (2005) 0.92

A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis (2012) 0.92

Heterozygosity for a mutation in the growth hormone-releasing hormone receptor gene does not influence adult stature, but affects body composition. J Clin Endocrinol Metab (2007) 0.92

Chemotherapy for the biliary tract cancers: moving toward improved survival time. J Gastrointest Cancer (2012) 0.92

Impact of fluconazole prophylaxis on cortisol levels in critically ill surgical patients. Antimicrob Agents Chemother (2004) 0.92

Expanded endonasal endoscopic approach for resection of a growth hormone-secreting pituitary macroadenoma coexistent with a cavernous carotid artery aneurysm. J Clin Neurosci (2012) 0.91

Detection of pituitary antibodies by immunofluorescence: approach and results in patients with pituitary diseases. J Clin Endocrinol Metab (2014) 0.91

Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. Clin Colorectal Cancer (2011) 0.91

The medical oncologist's role in palliative care: AIOM's position. Tumori (2010) 0.91

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. Clinicoecon Outcomes Res (2013) 0.91

Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism. J Med Chem (2008) 0.90

Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol (2013) 0.90

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer (2010) 0.90

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res (2014) 0.89

Adipokine profile and urinary albumin excretion in isolated growth hormone deficiency. J Clin Endocrinol Metab (2009) 0.89

Drug-induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol Res (2004) 0.89

Complications and death among elderly patients undergoing pituitary tumour surgery. Clin Endocrinol (Oxf) (2010) 0.88

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. Breast Cancer Res Treat (2014) 0.88

Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. Glia (2002) 0.87

Premetastatic niche: ready for new therapeutic interventions? Expert Opin Ther Targets (2012) 0.87

Intradermal lymphoscintigraphy at rest and after exercise: a new technique for the functional assessment of the lymphatic system in patients with lymphoedema. Nucl Med Commun (2010) 0.87

Isolated GH deficiency due to a GHRH receptor mutation causes hip joint problems and genu valgum, and reduces size but not density of trabecular and mixed bone. J Clin Endocrinol Metab (2013) 0.87

Pituitary antibodies in women with Hashimoto's thyroiditis: prevalence in diagnostic and prediagnostic sera. Thyroid (2012) 0.87

Antitumor effects of curcumin and structurally beta-diketone modified analogs on multidrug resistant cancer cells. Bioorg Med Chem Lett (2007) 0.87

Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy. Leuk Lymphoma (2011) 0.86

Pituitary and systemic autoimmunity in a case of intrasellar germinoma. Pituitary (2009) 0.86

Skin acrometastases in squamous cell carcinoma of the tongue. J Clin Oncol (2007) 0.85

Stilbene-based anticancer agents: resveratrol analogues active toward HL60 leukemic cells with a non-specific phase mechanism. Bioorg Med Chem Lett (2006) 0.85

A liquid chromatography-tandem mass spectrometry method for the determination of 5-Fluorouracil degradation rate by intact peripheral blood mononuclear cells. Ther Drug Monit (2009) 0.85

Overcoming cultural barriers to giving bad news: feasibility of training to promote truth-telling to cancer patients. J Cancer Educ (2009) 0.85

Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol (2013) 0.85

Predictors of access to pituitary tumor resection in the United States, 1988-2005. Eur J Endocrinol (2009) 0.84

Ultrasound features of medullary thyroid carcinoma correlate with cancer aggressiveness: a retrospective multicenter study. J Exp Clin Cancer Res (2014) 0.84

Diseases associated with growth hormone-releasing hormone receptor (GHRHR) mutations. Prog Mol Biol Transl Sci (2009) 0.84

A systematic review of experimental and clinical acupuncture in chemotherapy-induced peripheral neuropathy. Evid Based Complement Alternat Med (2013) 0.84

Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software. Eur J Hum Genet (2006) 0.84

Tumors of ampulla of Vater: A case series and review of chemotherapy options. World J Gastrointest Oncol (2012) 0.84

Predictors of existential and religious well-being among cancer patients. Support Care Cancer (2010) 0.84

Design, synthesis and biological evaluation of novel stilbene-based antitumor agents. Bioorg Med Chem (2008) 0.83

Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. Oncol Rep (2006) 0.83

Effects of recombinant mouse growth hormone treatment on growth and body composition in GHRH knock out mice. Growth Horm IGF Res (2005) 0.83

Clinical features of sellar and suprasellar meningiomas. Pituitary (2014) 0.83

ACTH-secreting pituitary microadenomas are associated with a higher prevalence of central hypothyroidism compared to other microadenoma types. Clin Endocrinol (Oxf) (2012) 0.82

Lifetime congenital isolated GH deficiency does not protect from the development of diabetes. Endocr Connect (2013) 0.82

Partial reversibility of growth hormone (GH) deficiency in the GH-releasing hormone (GHRH) knockout mouse by postnatal treatment with a GHRH analog. Endocrinology (2004) 0.82

Unusual sites of metastatic malignancy: case 1. Cardiac metastasis in hepatocellular carcinoma. J Clin Oncol (2004) 0.82

Prognostic value of exercise echocardiography in diabetic patients. Cardiovasc Ultrasound (2009) 0.82

Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy. J Exp Clin Cancer Res (2008) 0.82

Acupuncture in the treatment of menopause-related symptoms in women taking tamoxifen. Tumori (2002) 0.82

Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation. Breast Cancer Res Treat (2003) 0.82